Search

An international study led by MSK researchers has found that, when used to treat large B cell lymphoma, CAR T immunotherapy may work better when given earlier in the day.

… Monday, January 5, 2026 When it comes to giving immunotherapy to people with the most common form of lymphoma, the time of day may make a difference, according to new research from Memorial Sloan Kettering Cancer Center (MSK). People who receive chimeric antigen receptor (CAR) T cell therapy in the morning

Fourth-year student Jeff Smith received a Breast Cancer Research Program Predoctoral Traineeship Award from the Department of Defense Congressionally Directed Medical Research Programs.

… Monday, March 15, 2010 Fourth-year student Jeff Smith received a Breast Cancer Research Program Predoctoral Traineeship Award from the Department of Defense Congressionally Directed Medical Research Programs. This award is made based on the recipient’s talent, potential, and commitment to breast cancer

The pandemic has raised important issues for clinicians, and, after weighing the risks and benefits, the Colorectal Disease Management Team at MSK decided that all patients with locally advanced colorectal cancer will be treated with short-course radiation therapy rather than standard long-course chemoradiation therapy.

… Monday, May 11, 2020 The COVID-19 pandemic is consuming a significant amount of healthcare resources, especially in New York City, which became the global epicenter of the outbreak at the end of March 2020. Given the concerns around rapidly rising infection rates, impending staffing shortages, and the

Breakthrough findings illustrate the promise of precision oncology and signify a paradigm shift in drug development. Interim data from three trials show a 76 percent confirmed overall response rate in patients treated with the TRK inhibitor.

… Saturday, June 3, 2017 Larotrectinib (LOXO-101) has demonstrated consistent and durable antitumor activity in tropomyosin receptor kinase (TRK) fusion cancers across a wide range of patient ages and tumor types and was well tolerated by patients, according to results from three clinical trials presented

A study from investigators in the Sloan Kettering Institute uncovers the details of how a key protein called GRP94 becomes disrupted, leading to cancer and other diseases.

… Tuesday, June 30, 2020 Summary A study from investigators in the Sloan Kettering Institute reveals how a protein called GRP94, which is normally a “good guy” in the cell, turns bad when it has a sugar molecule added to it. In molecular biology, chaperones are a class of proteins that help regulate how

Learn about the latest treatments for colon and rectal (colorectal) cancer at Memorial Sloan Kettering Cancer Center.

… Tuesday, January 13, 2026 Colorectal cancer , which includes cancer of both the  colon and the  rectum , is the third most common cancer in both men and women in the United States. There is encouraging news about the disease on many fronts. Overall, the incidence of colorectal cancer is decreasing, and

Approaches used for research into the social lives of bacteria can also be used to explore how tumors behave and evolve.

… Thursday, May 1, 2014 Summary Approaches used for research into the social lives of bacteria can also be used to explore how tumors behave and evolve. Computational biologist Joao Xavier has spent most of his career researching how bacterial cells interact with one another and produce complex group behaviors

The FDA has approved the targeted drug repotrectinib for patients 12 and older with tumors that carry gene changes called NTRK fusions. The trial that resulted in the approval was led by MSK investigators.

… Thursday, June 13, 2024 On June 13, 2024, a targeted drug called  repotrectinib (Augtyro TM ) received accelerated approval from the US Food and Drug Administration (FDA) for treating cancers caused by gene changes called  NTRK fusions. The clinical trial that resulted in the approval was led globally

A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center.

… Thursday, May 19, 2011 A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center. The findings, which

Pituitary adenomas continue to grow in a small subset of patients despite treatment with standard surgery and radiotherapy. Recognizing the significant unmet needs in this cohort, we recently published a review of the latest treatment options.

… Wednesday, October 14, 2020 Pituitary adenomas continue to grow in a small subset of patients despite treatment with standard surgery and radiotherapy. Further treatments may provide symptom relief but are rarely definitive for disease management in this cohort. Recognizing the significant unmet needs